Veloxis Pharmaceuticals Overview and Company Details

Author

Reads 8.8K

Close-up Photo of Laboratory Glass Samples
Credit: pexels.com, Close-up Photo of Laboratory Glass Samples

Veloxis Pharmaceuticals is a company that specializes in developing and commercializing innovative products for the treatment of various diseases. The company was founded in 2001.

Veloxis Pharmaceuticals is headquartered in Denmark. The company has a strong presence in the pharmaceutical industry, with a focus on developing products that meet the needs of patients and healthcare professionals.

Veloxis Pharmaceuticals has a portfolio of products that are used to treat various conditions, including immunosuppression and inflammatory diseases.

Company Information

Veloxis Pharmaceuticals is a company with a clear leadership structure. Stacy Wheeler is the CEO of Veloxis Pharmaceuticals, Inc..

Where Is Based?

Veloxis Pharmaceuticals, Inc. is based in Cary, North Carolina.

NaICS Code for Inc

Veloxis Pharmaceuticals, Inc. has a NAICS code of 54171, which is also listed as 541711. This code is used for pharmaceutical preparation manufacturing.

The NAICS code for Veloxis Pharmaceuticals, Inc. also includes the broader categories of 5417 and 54. These codes encompass various types of manufacturing and professional services.

The company's NAICS code can be broken down further into more specific categories, including 33 and 541.

CEO of Inc

Interior of modern office lounge zone with sofa and armchair with table near window next to TV on wall and neon signboard with text do what you love near door
Credit: pexels.com, Interior of modern office lounge zone with sofa and armchair with table near window next to TV on wall and neon signboard with text do what you love near door

Stacy Wheeler is the CEO of Veloxis Pharmaceuticals, Inc.. She's the one in charge of making important decisions for the company.

The CEO plays a crucial role in shaping the company's direction and goals. Stacy Wheeler is responsible for overseeing the overall strategy and operations of Veloxis Pharmaceuticals, Inc..

Inc. Employee Count

Veloxis Pharmaceuticals, Inc. has a relatively small workforce with 122 people employed.

The company's employee count is likely a result of its focused approach to pharmaceutical research and development.

Veloxis Pharmaceuticals, Inc. has a dedicated team of 122 professionals working together to drive innovation in the industry.

Asahi Kasei Acquisition

Asahi Kasei Corporation completed its acquisition of US-based Veloxis Pharmaceuticals Inc. on March 3, 2020.

Veloxis Pharmaceuticals Inc. is a wholly owned US-based subsidiary of Veloxis Pharmaceuticals A/S, a specialty pharmaceutical company based in Denmark.

The acquisition provides Asahi Kasei with a business platform in the pharmaceutical industry of the USA.

A Group of People Having a Meeting in the Office
Credit: pexels.com, A Group of People Having a Meeting in the Office

Asahi Kasei aims to achieve synergies through the acquisition, such as enhancing licensing activity to obtain new pharmaceuticals.

This will be done by leveraging Asahi Kasei's business platform in Japan and Asia together with Veloxis' business platform in the U.S.

Asahi Kasei also plans to discover and develop new pipeline opportunities that will meet high unmet medical needs.

This will be achieved by combining Asahi Kasei's drug discovery capabilities and Veloxis' expertise in the US market.

The acquisition process began with a tender offer for shares and warrants of Veloxis Pharmaceuticals A/S on December 12, 2019.

The tender offer expired on January 14, 2020, and all procedures related to it were completed on March 3, 2020.

Veloxis Pharmaceuticals Inc. will continue to be managed by its current management team.

Recommended read: Ubs Acquire Credit Suisse

Veloxis Pharmaceuticals

Veloxis Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing immunosuppressive therapies. They have a strong presence in the market with their products being used in various countries.

Credit: youtube.com, CEoT 2023 Symposium Presented by Veloxis Pharmaceuticals Inc

Their lead product, Envarsus, is a proprietary formulation of tacrolimus that is used to prevent organ rejection in transplant patients. It has a unique pharmacokinetic profile that allows for once-daily dosing.

Veloxis Pharmaceuticals has a significant partnership with Astellas Pharma, a leading Japanese pharmaceutical company. This partnership has helped Veloxis to expand its global reach and commercialize Envarsus in multiple countries.

Envarsus has been shown to be effective in reducing the risk of acute rejection in kidney transplant patients. In clinical trials, it demonstrated a 50% reduction in the risk of acute rejection compared to the reference product.

Veloxis Pharmaceuticals is headquartered in the United States, with operations in several countries around the world. They have a strong team of experienced professionals who are dedicated to advancing the field of immunosuppression.

If this caught your attention, see: Altegrity Risk International

Company Structure

Veloxis Pharmaceuticals has a clear leadership structure in place. Daisuke Matsuo serves as the Chief Executive Officer, overseeing the company's overall direction.

Laboratory Interior
Credit: pexels.com, Laboratory Interior

The company's management team is rounded out by Ulf Meier-Kriesche, who joined as Chief Technology/Science/R&D Officer in 2017. Stacy Wheeler has been the Chief Operating Officer since 2016, bringing stability to the role.

Here is a brief overview of the key management team members:

  • Daisuke Matsuo - Chief Executive Officer
  • Ulf Meier-Kriesche - Chief Technology/Science/R&D Officer (since 2017-09-12)
  • Stacy Wheeler - Chief Operating Officer (since 2016-02-29)

SIC Code for Inc

Veloxis Pharmaceuticals, Inc. has a SIC code of 372.

If you're trying to research a company's structure, knowing its SIC code can be super helpful.

The SIC code for Veloxis Pharmaceuticals, Inc. is also 28, and 37.

Managers and Directors

When managing a team, it's essential to have the right people in the right positions. Daisuke Matsuo is the CEO of Veloxis Pharmaceuticals A/S.

The CEO is responsible for making key decisions, and it's clear that Matsuo is the top executive at the company.

Ulf Meier-Kriesche has been the CTO since September 12, 2017. This suggests that Meier-Kriesche has been instrumental in driving the company's technological advancements.

Stacy Wheeler has been the COO since February 29, 2016, making her a key player in the company's operations.

Here's a breakdown of the key managers and directors at Veloxis Pharmaceuticals A/S:

Financials and News

Credit: youtube.com, John Weinberg | Veloxis

Veloxis Pharmaceuticals has seen significant financial growth over the years, with net sales increasing from 2.65B in 2017 to 3.48B in 2018.

The company's net income has also improved, with a decrease from -840M in 2017 to -465M in 2018. Notably, Veloxis Pharmaceuticals' net debt has increased, reaching 2.74B in 2018.

Here is a comparison of the company's financials for 2017 and 2018:

The company has also been in the news for various developments, including the announcement of a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA in 2021.

Latest News:

Veloxis Pharmaceuticals A/S has been in the news for several significant events in recent years. In 2020, the company's shares were delisted from Nasdaq Copenhagen A/S on January 29th.

The company's financial guidance for 2019 was increased on October 30th of the same year. Veloxis Pharmaceuticals A/S reported earnings results for the third quarter ended September 30, 2019, on November 12th, 2019.

Person Holding Brown Leather Wallet with Embossed Brand Logo
Credit: pexels.com, Person Holding Brown Leather Wallet with Embossed Brand Logo

Veloxis Pharmaceuticals A/S entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA on April 25th, 2021. This move indicates the company's focus on expanding its portfolio and exploring new opportunities.

In 2020, Veloxis Pharmaceuticals A/S announced board appointments on February 17th. The company also announced the dosing of the first patient by partner Xenikos in the global Phase 3 study evaluating T-Guard(R) in patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) on June 28th, 2022.

Here's a summary of some key dates for Veloxis Pharmaceuticals A/S:

In May 2024, Veloxis Pharmaceuticals A/S selected to present at the 2024 American Transplant Congress in Philadelphia.

Financials

The financials of a company are a crucial aspect of its overall health and performance. The data from 2017 and 2018 shows a significant increase in net sales for the company.

Net sales for 2017 were $30.17M, $25.98M, $22.52M, $42.28M, $2.65B, $46.45M, $284M, $110M, $1.27B, $113M, $111M, and $4.58B. In 2018, net sales increased to $39.49M, $34.01M, $29.49M, $55.35M, $3.48B, $60.81M, $372M, $144M, $1.66B, $148M, $145M, and $5.99B.

See what others are reading: Sales Consultant Companies

Credit: youtube.com, Bloomberg Business News Live

The company's net income saw a decline in both years, with losses of $-9.54M, $-61.36M, $-8.22M, $-7.58M, $-7.12M, $-13.37M, $-840M, $-14.69M, $-89.91M, $-34.84M, $-400M, $-35.79M, $-35.05M, and $-1.45B in 2017, and $-5.28M, $-33.98M, $-4.55M, $-4.2M, $-3.95M, $-7.41M, $-465M, $-8.14M, $-49.8M, $-19.29M, $-222M, $-19.82M, $-19.41M, and $-802M in 2018.

The net debt of the company also increased, with values of $18.05M, $116M, $15.55M, $14.35M, $13.48M, $25.3M, $1.59B, $27.8M, $170M, $65.9M, $758M, $67.7M, $66.31M, and $2.74B in 2017, and $29.38M, $189M, $25.31M, $23.35M, $21.94M, $41.18M, $2.59B, $45.25M, $277M, $107M, $1.23B, $110M, $108M, and $4.46B in 2018.

Here's a summary of the company's net sales and net income for both years:

Maurice Pollich

Senior Writer

Maurice Pollich is a seasoned writer with a keen interest in the digital world. With a background in technology and finance, he brings a unique perspective to his writing. Maurice's expertise spans a range of topics, including cryptocurrency tokens, where he has developed a deep understanding of the underlying mechanics and market trends.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.